-
公开(公告)号：US20190031783A1
公开(公告)日：2019-01-31
申请号：US15914856
申请日：2018-03-07
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07K16/46 , C07K16/22 , A61K31/4745 , A61K31/495 , A61K31/513 , A61K31/525 , A61K31/7068 , A61K39/395 , A61K45/06 , A61K31/337 , C07K16/28 , A61K39/00
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
公开(公告)号：US09944720B2
公开(公告)日：2018-04-17
申请号：US14845511
申请日：2015-09-04
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07H21/04 , C12P21/06 , C12N1/12 , C12N1/20 , C12N15/00 , C12N5/00 , C07K16/46 , A61K45/06 , C07K16/22 , A61K39/395 , A61K31/513 , A61K31/7068 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/525 , C07K16/28 , C07K16/00 , A61K39/00
CPC classification number: C07K16/468 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/513 , A61K31/525 , A61K31/7068 , A61K39/395 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/28 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
公开(公告)号：US20250145688A1
公开(公告)日：2025-05-08
申请号：US18892964
申请日：2024-09-23
Applicant: AbbVie Inc. , Apogenix AG
Inventor： Fritz G. Buchanan , Christian Gieffers , Oliver Hill , Susan E. Lappe , Darren C. Phillips , Meinolf Thiemann
IPC: C07K14/705 , A61K38/00
Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
公开(公告)号：US20210040178A1
公开(公告)日：2021-02-11
申请号：US16993569
申请日：2020-08-14
Applicant: AbbVie Inc. , Apogenix AG
Inventor： Fritz G. Buchanan , Christian Gieffers , Oliver Hill , Susan E. Lappe , Darren C. Phillips , Meinholf Thiemann
IPC: C07K14/705
Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
公开(公告)号：US09908927B2
公开(公告)日：2018-03-06
申请号：US14694358
申请日：2015-04-23
Applicant: AbbVie Inc. , Apogenix AG
Inventor： Oliver Hill , Christian Gieffers , Meinolf Thiemann , Fritz G. Buchanan , Darren C. Phillips , Susan E. Lappe
CPC classification number: C07K14/70575 , A61K38/00 , C07K2319/00 , C07K2319/30
Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
Patent Agency Ranking
公开(公告)号：US20240174731A1
公开(公告)日：2024-05-30
申请号：US18352769
申请日：2023-07-14
Applicant: AbbVie Inc. , Apogenix AG
Inventor： Fritz G. Buchanan , Christian Gieffers , Oliver Hill , Susan E. Lappe , Darren C. Phillips , Meinholf Thiemann
IPC: C07K14/705 , A61K38/00
CPC classification number: C07K14/70575 , A61K38/00 , C07K2319/00 , C07K2319/30
Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
公开(公告)号：US20220403052A1
公开(公告)日：2022-12-22
申请号：US17588094
申请日：2022-01-28
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07K16/46 , A61K45/06 , C07K16/22 , A61K39/395 , A61K31/513 , A61K31/7068 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/525 , C07K16/28
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
8.发明申请ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF 有权ANTI-DLL4 / VEGF双变异型域免疫球蛋白及其用途公开(公告)号：US20140348835A1
公开(公告)日：2014-11-27
申请号：US14301546
申请日：2014-06-11
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07K16/46 , A61K31/4745 , A61K31/525 , C07K16/28 , A61K31/7068 , A61K31/337 , A61K31/513 , C07K16/22 , A61K39/395 , A61K31/495
CPC classification number: C07K16/468 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/513 , A61K31/525 , A61K31/7068 , A61K39/395 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/28 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
Abstract translation: 本文公开了多价和多特异性结合蛋白，制备结合蛋白的方法及其在诊断，监测，抑制，预防和/或治疗癌症，肿瘤和/或其它血管发生依赖性疾病中的用途，所述疾病以异常DLL4为特征 和/或VEGF表达或活性。
-
公开(公告)号：US20180222962A1
公开(公告)日：2018-08-09
申请号：US15887509
申请日：2018-02-02
Applicant: AbbVie Inc. , Apogenix AG
Inventor： Fritz G. Buchanan , Christian Gieffers , Oliver Hill , Susan E. Lappe , Darren C. Phillips , Meinholf Thiemann
IPC: C07K14/705
Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
10.发明申请ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF 审中-公开ANTI-DLL4 / VEGF双变异型域免疫球蛋白及其用途公开(公告)号：US20160122439A1
公开(公告)日：2016-05-05
申请号：US14845511
申请日：2015-09-04
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
CPC classification number: C07K16/468 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/513 , A61K31/525 , A61K31/7068 , A61K39/395 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/28 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
Abstract translation: 本文公开了多价和多特异性结合蛋白，制备结合蛋白的方法及其在诊断，监测，抑制，预防和/或治疗癌症，肿瘤和/或其它血管发生依赖性疾病中的用途，所述疾病以异常DLL4为特征 和/或VEGF表达或活性。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.019 seconds)
